Boston-based Alexion Pharmaceuticals develops medicine for rare diseases. Among its products are a treatment for a rare blood disease as well as the only approved complement inhibitor to treat a rare central nervous system disorder. In April, the company reported first quarter total revenue of $1.6 billion, a 13% increase from the same quarter last year. After almost 30 years as an independent company, Alexion announced in May that its shareholders approved an agreement for the company to be acquired by AstraZeneca. The acquisition is expected to be finalized in the third quarter of 2021. Nearly 90% of Alexion’s shares are held by institutions, including its two biggest shareholders, Vanguard Group and BlackRock.
Lists ranking Alexion Pharmaceuticals
Latest news for Alexion Pharmaceuticals